Arthneeti
Financial resultsMajor developmentFiled on BSE ·

Shilpa Medicare Q1 results approved; consolidated net profit Rs. 10,088 lakhs

Shilpa Medicare · Pharmaceuticals & Biotechnology

Arthneeti Research DeskPublished 1 min read

Key highlights

  • Board approved unaudited standalone and consolidated results for quarter ended 30th June, 2026; consolidated net profit Rs. 10,088 lakhs vs Rs. 4,688 lakhs for 30.06.2025.
  • Board approved appointment of Mr. Sharath Reddy Kalakota (DIN: 03603460), Whole time Director, liable to retire by rotation, subject to members' approval at the AGM on 11th September 2026.
  • Biocare's proposed investment in Gate2Brain, aggregating up to EUR 7 million, is to be made in a fungible manner through cash infusion/equity for services/development of projects.

Why it's rated major development: the year-on-year change is 115% (50% or more)

Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.

Original filing

Board Meeting Outcome for Unaudited Financial Results For The Quarter Ended 30 June, 2026

Read the filing on BSE (PDF) →

Companies guiding to strong growth

Ranked by management's own guidance on revenue and margins — not by us.

Rossell Techsys

Aerospace & Defense

Revenue growth 40%+Margin up 2%+

Sign up free to see all 6 →

See full rankings

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

More from Shilpa Medicare

Other financial results filings this fortnight

All financial results filings →

Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.